De-escalation in HPV-associated oropharyngeal cancer: lessons learned from the past? A critical viewpoint and proposal for future research.
Petar SutonSkelin MarkoLuksic IvicaPublished in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2021)
Data obtained with de-intensified strategies should only serve to help select an appropriate experimental arm for a randomized controlled trial phase III comparison against cisplatin and 70 Gy of radiotherapy. Without a proper randomized trial, there remains the possibility of compromising survival, which raises ethical questions about conducting any de-escalation trial.
Keyphrases
- phase iii
- open label
- phase ii
- clinical trial
- papillary thyroid
- study protocol
- early stage
- locally advanced
- radiation therapy
- squamous cell
- current status
- double blind
- big data
- radiation induced
- placebo controlled
- randomized controlled trial
- childhood cancer
- lymph node metastasis
- squamous cell carcinoma
- machine learning
- free survival
- rectal cancer
- clinical evaluation